[1]Gaona LP, Medina LA, Maga PK. Epidemiology of ovarian cancer [J]. Chin Clin Oncol, 2020,9(4): 47.
[2]Liu B, Nash J, Runowicz C, et al. Ovarian cancer immunotherapy: opportunities, progresses and challenges [J]. J Hematol Oncol, 2010,3(1):7-18.
[3]Mei Y, Zhang L, Yang H, et al. Regulatory effect of grainyhead-like 2 gene on proliferation of epithelial ovarian cancer cells by nuclear factor erythroid-2-related factor 2 transcription [J]. Acta Anatomica Sinica,2019,50(4):477-482. (in Chinese)
梅燕,张琳,杨红,等.核因子E2相关因子2转录调控粒状头样2基因影响上皮性卵巢癌细胞活力[J].解剖学报,2019,50(4):477-482.
[4]Loret N, Denys H, Tummers P, et al. The role of epithelial-to-mesenchymal plasticity in ovarian cancer progression and therapy resistance [J]. Cancers, 2019,11(6):838-860.
[5]Koutsaki M, Spandidos DA, Zaravinos A. Epithelial-mesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics [J]. Cancer letters, 2014,351(2): 173-181.
[6]Zhang X, Jiang ZhM, Cheng XY, et al.MicroRNA-98-5p targeting ribonucleotide reductase small subunit M2 regulating cisplatin resistance in cervical cancer cells [J]. Acta Anatomica Sinica,2021,52(3):432-438. (in Chinese)
张霞,蒋志明,程晓燕,等.微小RNA-98-5p靶向调控核糖核苷酸还原酶小亚基M2调控宫颈癌细胞顺铂的耐药性[J].解剖学报,2021,52(3):432-438.
[7]Wu H, Liu J, Zhang Y, et al. miR-22 suppresses cell viability and EMT of ovarian cancer cells via NLRP3 and inhibits PI3K/AKT signaling pathway [J]. Clin Transla Oncology, 2021,23(2): 257-264.
[8]Zhao LL, Li R, Xu SL, et al. Tumor suppressor miR-128-3p inhibits metastasis and epithelial-mesenchymal transition by targeting ZEB1 in esophageal squamous-cell cancer[J]. Acta Biochim Biophys Sin(Shanghai), 2018, 50(2): 171-180.
[9]Bai J, Zhang X, Shi DD, et al. Exosomal miR-128-3p promotes epithelial-to-mesenchymal transition in colorectal cancer cells by targeting FOXO4 via TGF-β/SMAD and JAK/STAT3 Signaling[J]. Front Cell Dev Biol, 2021,9:568738.
[10] Feng W, Guo RX, Zhang DY, et al. Circ-ABCB10 knockdown inhibits the malignant progression of cervical cancer through microRNA-128-3p/ZEB1 axis[J]. Biol Proced Online, 2021,23(1): 17.
[11]Zhu L, Wang A, Gao M, Duan X, Li Z. LncRNA MIR4435-2HG triggers ovarian cancer progression by regulating miR-1283p/CKD14 axis[J]. Cancer Cell Int, 2020, 20:145.
[12]Wang Q, Li XP, Zhou X, et al. A single-nucleotide polymorphism in lnc-LAMC2-1:1 interferes with its interaction with miR-128 to alter the expression of deleted in colorectal cancer and its effect on the survival rate of subjects with ovarian cancer[J]. J Cell Biochem, 2020, 129(1): 227-232.
[13]Shi Y, Yan FG, Wang FP, et al. MiR-128-3p suppresses tumor proliferation and metastasis via targeting CDC6 in hepatocellular carcinoma cells[J]. Tissue Cell, 2021,72:101534.
[14]Liu YY, Fu XM, Wang XY, et al. Long non-coding RNA OIP5-AS1 facilitates the progression of ovarian cancer via the miR-128-3p/CCNG1 axis.[J]. Mol Med Rep, 2021, 23(5):388-399.
[15]Elsayed AM, Amero P, Salama SA, et al. Back to the future: rethinking the great potential of lncRNA(S) for optimizing chemotherapeutic response in ovarian cancer[J]. Cancers(Basel), 2020,12(9):2406.
[16]Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1[J]. Nat Cell Biol, 2008,10(5):593-601.
[17]Frixa T, Sacconi A, Cioce M, et al. MicroRNA-128-3p-mediated depletion of Drosha promotes lung cancer cell migration[J]. Carcinogenesis. 2018,39(2): 293-304.
|